Whether your personal interests are in supporting innovation, bringing lifesaving biomedical products to patients, training the next generation of biomedical leaders or fueling our economy, the Center for Biotechnology provides a vehicle to accomplish great things. Things that matter. Things that change, and save, lives.
Your involvement is an essential part of our future. Please consider a gift to the Center for Biotechnology which will help fuel innovation by ensuring that lifesaving technologies make it out of research labs and into the hands of patients.
Give to the Center for Biotechnology online through the Stony Brook Foundation. Contributions can be made to our Fund for Excellence. More information about donating through the Stony Brook Foundation can be found here.
The Life Sciences Summit is an exclusive early stage investor and business development conference that highlights innovation. The objective of the event is to provide an intimate setting allowing emerging biotech companies and academic innovators to connect with the capital and strategic partners they will need to move new discoveries through clinical development.
The virtual 2022 program features thought provoking plenary sessions, presentations by promising young companies with transformative science, the “innovation pipeline” featuring academic innovators and pre-seed stage companies working on cutting edge technologies, and 1:1 networking opportunities.
The Center for Biotechnology is pleased to announce a request for proposals for our Research Evaluation and Commercialization Hub (REACH) award program. Awards will be in two categories: Feasibility ($50k/12mo) and Proof of Concept ($100K/12 mo.) Details on the full funding program overview and proposal guidelines can be found here.
The development of promising innovations often stalls due to limited early-stage funding to address translational uncertainties. The Center for Biotechnology's Research Evaluation and Commercialization Hub (REACH) award program bridges the translation gap between biomedical discovery and their development toward commercial goals. Program funding is intended to determine feasibility, develop proof-of-concept, and ultimately lead to follow-on funding, a strategic partnership, or company formation.
The REACH program supports faculty and postdoctoral researchers in translating bio-based, bio-convergence, and bio-medical research discoveries by providing targeted funding and strategic guidance to bridge the translation gap between discovery and development for commercialization.
[post_title] => Funding Opportunity: Research Evaluation and Commercialization Hub (REACH)Awards
[post_excerpt] => The Center for Biotechnology is pleased to announce a request for proposals for our REACH award program. Awards will be in two categories: Feasibility ($50k/12mo) and Proof of Concept ($100K/12 mo.)
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => news-reach25
[to_ping] =>
[pinged] =>
[post_modified] => 2025-03-24 12:11:36
[post_modified_gmt] => 2025-03-24 16:11:36
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=4804
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[1] => WP_Post Object
(
[ID] => 4488
[post_author] => 4
[post_date] => 2024-10-24 10:45:00
[post_date_gmt] => 2024-10-24 14:45:00
[post_content] =>
Governor Kathy Hochul has unveiled plans for New York BioGenesis Park, a groundbreaking $430 million Cell and Gene Therapy (CGT) Innovation Hub in Nassau County, Long Island. To be developed by The Albanese Organization, Inc., this state-of-the-art facility would catalyze CGT research, development, clinical manufacturing, and commercialization across New York State. With a historic $150 million state investment—the largest nationwide for a cell and gene therapy hub—NYBGP would accelerate the delivery of new therapies from lab to patient in New York's diverse communities. This transformative hub aims to establish New York as the leading global destination for CGT innovation, driving economic growth, attracting top talent, and revolutionizing patient care statewide and beyond.
The Center for Biotechnology is thrilled to be counted as a partner in this effort, and is looking forward to working with our colleagues in the initiative to help catalyze and accelerate life-changing therapies.
New York BioGenesis Park is envisioned as a cutting-edge, full-service campus dedicated to advancing cell and gene therapies and accelerating their commercialization. At full build-out, the 700,000-square-foot park would create an end-to-end Cell and Gene Therapy innovation and supply center, featuring interconnected areas for public engagement, research, manufacturing, and collaboration.
A cornerstone of New York BioGenesis Park is its incubator, supported by a $50 million investment from ESD's Long Island Investment Fund. This facility will empower early-stage therapeutic developers by offering state-of-the-art wet lab space, shared equipment, office space, and other essential resources. This nurturing environment will provide Cell and Gene Therapy companies with access to specialized equipment, mentoring, and stage-appropriate financial guidance. As a critical component of New York BioGenesis Park, the incubator is poised to catalyze the growth of promising Cell and Gene Therapy companies by providing them with resources and support, unlocking their potential for innovation and success.
New York BioGenesis Park would foster strong ties with academic and medical institutions throughout New York, creating a robust ecosystem for Cell and Gene Therapy innovation. Collaborating with the Empire State Cellular Therapy Consortium and world-class institutions like Cold Spring Harbor Laboratory, the Feinstein Institutes, Northwell Health, Roswell Park, Stony Brook University, Weill Cornell, Columbia University and others around the state, New York BioGenesis Park would enhance research synergies and accelerate medical breakthroughs. This ecosystem would bring together experts in advanced Cell and Gene Therapy therapies, offering specialized facilities, services, and resources to both tenants and collaborating institutions. By facilitating cutting-edge science, innovative technology development and novel approaches to clinical trials, New York BioGenesis Park would ensure New York's institutions remain globally competitive in groundbreaking Cell and Gene Therapy research and commercialization.
[post_title] => Long Island to be location for Nation-Leading Cell and Gene Therapy Innovation Hub: New York BioGenesis Park.
[post_excerpt] =>
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => long-island-to-be-location-for-nation-leading-cell-and-gene-therapy-innovation-hub-new-york-biogenesis-park
[to_ping] =>
[pinged] =>
[post_modified] => 2025-02-26 16:35:20
[post_modified_gmt] => 2025-02-26 21:35:20
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=4488
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[2] => WP_Post Object
(
[ID] => 3973
[post_author] => 4
[post_date] => 2022-12-08 15:00:38
[post_date_gmt] => 2022-12-08 15:00:38
[post_content] =>
The 9th annual Immuno-Oncology 360° Summit, taking place February 7-10, 2023 in Brooklyn, NY, offers an unparalleled opportunity to hear from stakeholders representing both the science and business communities who report on the latest data impacting IO.
Center for Biotechnology constituents receive a 15% Discount on registration with code "CFB15"
[post_title] => Join us at io360! February 7-10 in Brooklyn NY
[post_excerpt] => Join us at io360 in February!
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => join-us-at-io360-february-7-10-in-brooklyn-ny
[to_ping] =>
[pinged] =>
[post_modified] => 2024-08-22 11:32:03
[post_modified_gmt] => 2024-08-22 15:32:03
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=3973
[menu_order] => 11
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[3] => WP_Post Object
(
[ID] => 3107
[post_author] => 3
[post_date] => 2018-12-18 16:28:18
[post_date_gmt] => 2018-12-18 16:28:18
[post_content] => The Center for Biotechnology will be hosting our annual SBIR/STTR NIH Focused Workshop on January 15-16, 2019.
Did you know that the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) SBIR/STTR programs award over $2.6 billion in high-risk, non-diluted R&D funding annually to qualified small businesses?
Learn more about SBIR/STTR funding at this 1.5-day session focused on the National Institutes of Health (NIH) which will cover program essentials and how to compete for funding. Training will include:
– Current information on the SBIR/STTR programs
– Strategies for targeting your proposal to address the mission and requirements of the NIH
– How to approach each section of your proposal
– Planning your commercialization strategy
– Writing to meet the reviewers’ expectations
Tuesday, January 15, 2019, 8:30am – 4:30pm
Wednesday, January 17, 2019, 8:30am –12:00pm
Location: Long Island High Technology Incubator
Main Conference Room
25 Health Sciences Drive
Stony Brook, NY 11794
Registration Fee: $60 | Space is Limited. Pre-registration is required.
REGISTER ONLINE
[post_title] => SBIR/STTR INTENSIVE WORKSHOP: NIH FOCUSED
[post_excerpt] => The Center for Biotechnology will be hosting our annual SBIR/STTR NIH Focused Workshop on January 15-16, 2019.
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => sbirsttr-intensive-workshop-nih-focused
[to_ping] =>
[pinged] =>
[post_modified] => 2019-01-24 15:35:16
[post_modified_gmt] => 2019-01-24 15:35:16
[post_content_filtered] =>
[post_parent] => 0
[guid] => http://centerforbiotechnology.org/?p=3107
[menu_order] => 107
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[4] => WP_Post Object
(
[ID] => 4373
[post_author] => 4
[post_date] => 2024-02-08 15:17:50
[post_date_gmt] => 2024-02-08 20:17:50
[post_content] =>
Save the date to join us in New York City for the expanded, two-day Life Sciences Summit™ 2024! Visit lifesciencessummit.org for program & registration updates.
[post_title] => Save the Date! LSS 2024: October 8-9th!
[post_excerpt] => Save the date to join us in New York City for the expanded, two-day Life Sciences Summit™ 2024!
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => save-the-date-lss-2024-october-9th
[to_ping] =>
[pinged] =>
[post_modified] => 2024-11-19 10:48:53
[post_modified_gmt] => 2024-11-19 15:48:53
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=4373
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
)
[post_count] => 5
[current_post] => -1
[before_loop] => 1
[in_the_loop] =>
[post] => WP_Post Object
(
[ID] => 4804
[post_author] => 4
[post_date] => 2025-03-20 12:10:54
[post_date_gmt] => 2025-03-20 16:10:54
[post_content] =>
The Center for Biotechnology is pleased to announce a request for proposals for our Research Evaluation and Commercialization Hub (REACH) award program. Awards will be in two categories: Feasibility ($50k/12mo) and Proof of Concept ($100K/12 mo.) Details on the full funding program overview and proposal guidelines can be found here.
The development of promising innovations often stalls due to limited early-stage funding to address translational uncertainties. The Center for Biotechnology's Research Evaluation and Commercialization Hub (REACH) award program bridges the translation gap between biomedical discovery and their development toward commercial goals. Program funding is intended to determine feasibility, develop proof-of-concept, and ultimately lead to follow-on funding, a strategic partnership, or company formation.
The REACH program supports faculty and postdoctoral researchers in translating bio-based, bio-convergence, and bio-medical research discoveries by providing targeted funding and strategic guidance to bridge the translation gap between discovery and development for commercialization.
